Kimberly Jones - Boston, MA

Associate

Representing founder and owner of investment advisor managing several private equity funds, facing allegations of misrepresentations to investors in the amount of $1.8 billion, in parallel SEC civil proceeding regarding the coordination and cooperation with SEC appointed monitorship and receivership.

Representing former CFO of NASDAQ-listed multinational telecommunications company in SEC investigation for revenue recognition issues.

Representing NYSE-listed energy company in investigations by Manhattan District Attorney and other state regulators on allegations of fraud in the heating oil industry, resulting in no charges.

Representing several trusts in state litigation by SEC appointed monitor of related investment fund over delinquent loans and failed claw-back, resulting in securing funds and accrued interest for trusts.

Representing prominent regional construction company and individuals in connection with Manhattan District Attorney investigation and prosecution on allegations of insurance fraud.

Representing whistleblower for alleged healthcare fraud, including Medicaid and Medicare fraud, in coordination with DOJ for potential qui tam lawsuit.

Representing major U.S. pharmaceutical company in global products liability litigation, including highly sensitive vaccine litigation in Japan.

Representing prominent medical device manufacturer facing allegations by DOJ, HHS OIG, and State AGs in connection with alleged violations of the FCA and AKS for bribery and payments to physicians, resulting in a $12.95 million settlement.

Representing former company president accused of trade secret misappropriation, defeating broad injunction sought against client.

Representing group of affiliated companies and individuals defending a RICO action on allegations of poaching employees and trade secret misappropriation.

Representing world-leading aerospace and government defense company in connection with anti-corruption reviews and investigations on allegations of foreign bribery charges, AECA and ITRA violations resulting in combined penalties of over $3.9 billion.